How Many Tests Does It Take to Diagnose a Triple-Hit B-Lymphoblastic Lymphoma? (Hint, It's A Lot).

Autor:	Das M; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA., Tsuchiya KD; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA.; Department of Laboratories, Seattle Children's Hospital, Seattle, WA, USA.; Now at Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA., Bohling SD; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA.; Department of Laboratories, Seattle Children's Hospital, Seattle, WA, USA., Davis B; Department of Laboratories, Seattle Children's Hospital, Seattle, WA, USA.; Now at CellNetix Pathology Laboratories, Tukwila, WA, USA., Hwang S; Department of Laboratories, Seattle Children's Hospital, Seattle, WA, USA.; Now at Department of Pathology, Orlando Health, Orlando, FL, USA., Gardner RA; Department of Pediatrics, University of Washington, Seattle, WA, USA.; Ben Towne Center of Childhood Cancer Research, Seattle Cancer Research Institute, Seattle, WA, USA., Chisholm KM; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA.; Department of Laboratories, Seattle Children's Hospital, Seattle, WA, USA.
Jazyk:	angličtina
Zdroj:	Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society [Pediatr Dev Pathol] 2024 Mar-Apr; Vol. 27 (2), pp. 193-197. Date of Electronic Publication: 2023 Nov 30.
DOI:	10.1177/10935266231212337
Abstrakt:	B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) is a precursor B-cell neoplasm that often harbors specific cytogenetic/molecular abnormalities with distinctive clinical, phenotypic, and prognostic characteristics. Subcategorization of B-ALL/LBL therefore requires extensive cytogenetic and/or molecular testing to determine the appropriate classification and therapeutic interventions for these patients. Herein, we present a case of a 17-year-old young woman diagnosed with B-LBL harboring not only an IGH::MYC rearrangement but also BCL2 and BCL6 rearrangements (so-called "triple-hit") and somatic biallelic TP53 inactivation. MYC rearrangements are relatively rare in B-ALL/LBL, and the identification of a "triple-hit" elicited an initial diagnostic dilemma. However, a multimodal approach allowed for the classification of this complex case and helped guide selection of an appropriate therapeutic regimen. Competing Interests: Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu